Revenue ($USD) : $7,124,100,000
R&D spend : $998,800,000
Employees : 13,676
Fiscal year end : 12/31/2023
CEO : Gary Guthart

www.intuitive.com

Intuitive widened the moat against the host of the companies — including giants Medtronic and Johnson & Johnson — that sought to challenge it in the soft-tissue surgical robotics space. It opened 2024 announcing that it submitted its next-gen da Vinci 5 system for FDA review. Two months later, it had da Vinci 5 clearance secured, with a limited launch phase expected to last into 2025. Analysts have expressed confidence that the new system will fuel future growth. As of the writing of this description in mid-August, Intuitive’s stock value was up more than 41% year-to-date. The da Vinci 5 joins Intuitive’s existing da Vinci robotic surgical system portfolio alongside the multiport X and Xi systems and the single-port SP. There is also Ion, Intuitive’s robotic-assisted platform for minimally invasive biopsy in the lung. Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi to enable new system capabilities and advanced digital experiences, now and in the future. The next-gen system also introduces Force Feedback technology and optional instruments that enable the system to measure subtle forces exerted on tissue during surgery and relay that feeling to surgeons. “We strive to provide customers with technology that meets their needs and solves important problems,” said Intuitive Chief Medical Officer Dr. Myriam Curet. –CN

MORE ON MDO: The Intuitive da Vinci 5’s top design changes: ‘This is groundbreaking for robotic surgery